(PDF) P3.17-22 Nivolumab Plus Cisplatin/Pemetrexed or

P3.17-22 Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable NSCLC

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1978

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

M. Werner-Wasik

Publisher

Elsevier BV

Related search

Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head

Journal of Clinical Oncology

Cancer Research

English

Weiterbehandlung Mit Pemetrexed Nach First-Line Pemetrexed/Cisplatin

Best Practice Onkologie

English

Phase I Dose-Escalation Study of Copanlisib in Combination With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

British Journal of Cancer

Cancer Research

English

Cost-Effectiveness of Gemcitabine Plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan

Value in Health

Occupational Health

English

P2.06-10 Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Malignant Pleural Mesothelioma: A Trial in Progress

Journal of Thoracic Oncology

Respiratory Medicine

English

Cisplatin Versus Cisplatin Plus Doxorubicin for Standard-Risk Hepatoblastoma

New England Journal of Medicine

English

Binimetinib Plus Gemcitabine and Cisplatin Phase I/Ii Trial in Patients With Advanced Biliary Cancers

Clinical Cancer Research

Cancer Research

English

A Phase II Study of Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Adenocarcinomas

British Journal of Cancer

Cancer Research

English

OA05.07 IMpower132: PFS and Safety Results With 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English